Advanced search
Publication Cover
Journal of Chemotherapy Volume 31, 2019 - Issue 4
Submit an article Journal homepage
91
Views
1
CrossRef citations to date
0
Altmetric
Antimicrobial Original Research Paper

Efficacy of tenofovir and entecavir in patients who relapsed after pegylated interferon therapy

Şükran KöseDepartment of Infectious Diseases and Clinical Microbiology, Tepecik Training and Research Hospital, İzmir, Turkey
,
Tuba Tatli KişDepartment of Infectious Diseases and Clinical Microbiology, Tepecik Training and Research Hospital, İzmir, TurkeyCorrespondence[email protected]
&
Sabri AtalayDepartment of Infectious Diseases and Clinical Microbiology, Tepecik Training and Research Hospital, İzmir, Turkey
Pages 209-213 | Received 19 Mar 2018, Accepted 13 Mar 2019, Published online: 09 Apr 2019

References

  • Andreani T. HBV-carriers: when is monitoring and surveillance sufficient? (point of view). Clin Res Hepatol Gastroenterol. 2011;35:813–18.
  • Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–1555.
  • Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the global burden of Disease Study 2013. Lancet. 2016;388:1081–1088.
  • Papastergiou V, Lombardi R, MacDonald D, Tsochatzis EA. Global epidemiology of hepatitis B virus (HBV) infection. Current Hepatol Rep. 2015;14:171–8.
  • Ay P, Torunoglu MA, Com S, Çipil Z, Mollahaliloğlu S, Erkoç Y, et al. Trends of hepatitis B notification rates in Turkey, 1990 to 2012. Eur Surv Rep. 2013;18(47):20636.
  • II. Viral Hepatitis Diagnosis and Treatment Guide. Viral Hepatitis J. 2008;13:87–96.
  • EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatology. 2017;67(2):370–398.
  • Chen CJ, Yang HI, Su J. Reveal HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus level. JAMA. 2006;295:65–73.
  • Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–86.
  • Melissa K, Osborn Anna S, Lok F. Antiviral options for the treatment of chronic hepatitis B. J Antimicrob Chemother. 2006;57(6):1030–1034.
  • Sonneveld M, Janssen HL. Pros and cons of peginterferon versus nucleos(t)ide analogues for Treatment of Chronic Hepatitis B. Curr Hepat Rep. 2010;9:91–8.
  • Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol. 2011;8:275.
  • Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. 2009;49(5):185–195.
  • EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatology. 2009;50(22):227–242.
  • Yamazhan T, Kurtaran B, Pullukçu H, Yüksel E, Özkaya D, Taşbakan MI, et al. Pegylated interferon in HBeAg-positive and -negative chronic hepatitis B patients: post-treatment 1-year results of three Turkish centres. J Chemother. 2014;26(6):339–41.
  • Shi H, Huang M, Lin G, Li X, Wu Y, Jie Y, et al. Efficacy comparison of tenofovir and entecavir in HBeAg-Positive Chronic Hepatitis B patients with high HBV DNA. BioMed Res Int. 2016 (2016):6725073.
  • Idilman R, Gunsar F, Koruk M, Keskin O, Meral CE, Gulsen M, et al. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting. J Viral Hepat. 2015;22:504–10.
  • Park JW, Kwak KM, Kim SE, Kim SE, Jang MK, Suk KT et al. Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients. BMC Gastroenterol. 2017;17:39.
  • Batirel A, Guclu E, Arslan F, Kocak F, Karabay O, Ozer S et al. Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naive patients with chronic hepatitis B: a multicenter real-life study. Int J Infect Dis. 2014;28:153–9.
  • Wan M, Weng X. Experts advice on treatment of chronic hepatitis B with interferon (update 2010). Chin J Infect Dis. 2010;28:193–200.
  • Cai S, Cao J, Yu T, Xia M, Peng J. Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection pre-treated with interferon compared with de novo therapy with entecavir and telbivudine. Medicine. 2017;96(22):7021.
  • Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886–893.
  • Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468–475.
  • Wi CI, Kim WR, Gross JB, Stadheim LM, Poterucha JJ. Potential efficacy of pegylated interferon-α and a nucleos(t)ide analogue as combination therapy for HBeAg-positive chronic hepatitis B. Gut Liver. 2016;10(4):611–6.
  • Xie Q, Zhou H, Bai X, Wu S, Chen JJ, Sheng J, et al. A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B "e" antigen-positive chronic hepatitis B. Clin Infect Dis. 2014;59(12):1714–23.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.